Satellos spends $4M (U.S.) on R&D in Q3 2025

Executive Summary

• Satellos Bioscience Inc. reported its financial results for the third quarter ended September 30, 2025, including a net loss of $5.8 million and cash reserves of $34.6 million.
• The company announced the appointment of Mark Nawacki to its Board of Directors to support strategic growth and clinical advancement.
• Significant clinical progress was reported for SAT-3247, including the submission of an IND application to the FDA for a Phase 2 pediatric study in Duchenne Muscular Dystrophy (DMD), parallel global regulatory filings, and new efficacy data from Phase 1b trials.

Key Details

• Financial Results (Q3 2025):
  • Net loss: $5.8 million ($0.03 loss per share), compared to a net loss of $6.6 million ($0.06 loss per share) in Q3 2024.
  • Cash and cash equivalents/short-term investments: $34.6 million as of Sept. 30, 2025 (down from $48.5 million at Dec. 31, 2024).
  • Research and Development (R&D) expenses: $4.0 million (up from $2.4 million in Q3 2024), driven by increased clinical trial costs.
  • General and Administrative (G&A) expenses: $2.0 million (up from $1.3 million in Q3 2024), driven by headcount changes and stock-based compensation.
  • The decrease in net loss was primarily due to a $2.9 million impairment of an intangible asset recognized in Q3 2024, partially offset by increased R&D and G&A expenses.
• Board Appointment:
  • Mark Nawacki appointed to the Board of Directors in November 2025.
  • Nawacki is the co-founder, president, and former CEO of Searchlight Pharma (acquired by Apotex in June 2024), bringing over two decades of experience in pharmaceuticals, corporate development, and M&A.
• Clinical Updates (SAT-3247 for Duchenne Muscular Dystrophy):
  • Phase 2 Pediatric Study: IND application submitted to the FDA in September 2025 to initiate a Phase 2 trial in ambulatory children with DMD. Parallel regulatory filings submitted in the UK, Europe, Serbia, and Australia. A filing was submitted to Health Canada on November 13, 2025.
  • Enrollment Timeline: Company expects to enroll the first patient into the Phase 2 study by the end of calendar 2025.
  • Phase 1b Data Presentation: New data presented at the 30th Annual Congress of the World Muscle Society showed:
    • 118.6% mean improvement in maximum grip strength (dominant hand).
    • 97.9% mean improvement in maximum grip strength (non-dominant hand).
    • 5.8% mean improvement in respiratory function (predicted forced vital capacity).
  • Long-Term Study (LT-001): First patient dosed in the open-label, long-term follow-up study for adult males with DMD.
  • Upcoming Data: Initial results from patients returning from the Phase 1b trial (after three months of total treatment) are expected in Q1 2026. Plans include expanding LT-001 into the United States.

Notable Quotes

• "The second half of 2025 represents another important milestone for Satellos as we advance toward initiating the global phase 2 pediatric study of SAT-3247 and continue to generate meaningful data in adults with Duchenne," said Wildon Farwell, MD, Satellos chief medical officer.
• "We are pleased to strengthen our strategic leadership with the addition of Mark Nawacki to the board of directors. Mark's extensive experience founding and developing organizations through disciplined growth, acquisitions and licensing will add valuable perspective as we prepare for the next stage of SAT-3247 development and Satellos' continued growth," said Frank Gleeson, co-founder and chief executive officer of Satellos.